Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15-79). The follow-up period was 8.32 years (2-16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19-11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09-9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: -4.00 [95% CI: -6.81 to -1.18]; p < 0.001 and mean difference: -5.36 [95% CI: -3.74 to -6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.

• Klíčová slova
• GCTB, bone, denosumab, neoplasia, targeted treatment,
• Publikační typ
• časopisecké články MeSH

• MeSH
• lidé MeSH
• pandemie * MeSH
• vyučování * MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Despite constant advances in the field of pediatric oncology, the survival rate of high-risk neuroblastoma patients remains poor. The molecular and genetic features of neuroblastoma, such as MYCN amplification and stemness status, have established themselves not only as potent prognostic and predictive factors but also as intriguing targets for personalized therapy. Novel thiosemicarbazones target both total level and activity of a number of proteins involved in some of the most important signaling pathways in neuroblastoma. In this study, we found that di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) potently decreases N-MYC in MYCN-amplified and c-MYC in MYCN-nonamplified neuroblastoma cell lines. Furthermore, DpC succeeded in downregulating total EGFR and phosphorylation of its most prominent tyrosine residues through the involvement of NDRG1, a positive prognostic marker in neuroblastoma, which was markedly upregulated after thiosemicarbazone treatment. These findings could provide useful knowledge for the treatment of MYC-driven neuroblastomas that are unresponsive to conventional therapies.

• Klíčová slova
• DpC, EGFR, MYC, NDRG1, lipid droplet, neuroblastoma, thiosemicarbazone,
• MeSH
• amplifikace genu účinky léků   MeSH
• biologické modely MeSH
• chelátory železa farmakologie   MeSH
• down regulace účinky léků   MeSH
• erbB receptory metabolismus   MeSH
• fosforylace účinky léků   MeSH
• fyziologický stres účinky léků   MeSH
• intracelulární signální peptidy a proteiny metabolismus   MeSH
• lidé MeSH
• nádorové buněčné linie MeSH
• neuroblastom metabolismus   patologie   MeSH
• proteiny buněčného cyklu metabolismus   MeSH
• protoonkogen n-myc metabolismus   MeSH
• protoonkogenní proteiny c-akt metabolismus   MeSH
• pyridiny farmakologie   MeSH
• signální transdukce * MeSH
• thiosemikarbazony farmakologie   MeSH
• tvar buňky účinky léků   MeSH
• umlčování genů účinky léků   MeSH
• upregulace účinky léků   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• chelátory železa MeSH
• di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone MeSH Prohlížeč
• erbB receptory MeSH
• intracelulární signální peptidy a proteiny MeSH
• N-myc downstream-regulated gene 1 protein MeSH Prohlížeč
• proteiny buněčného cyklu MeSH
• protoonkogen n-myc MeSH
• protoonkogenní proteiny c-akt MeSH
• pyridiny MeSH
• thiosemikarbazony MeSH

Tyrosine kinase inhibitors (TKIs) are being increasingly used to treat various malignancies. Although they were designed to target aberrant tyrosine kinases, they are also intimately linked with the mechanisms of multidrug resistance (MDR) in cancer cells. MDR-related solute carrier (SLC) and ATB-binding cassette (ABC) transporters are responsible for TKI uptake and efflux, respectively. However, the role of TKIs appears to be dual because they can act as substrates and/or inhibitors of these transporters. In addition, several TKIs have been identified to be sequestered into lysosomes either due to their physiochemical properties or via ABC transporters expressed on the lysosomal membrane. Since the development of MDR represents a great concern in anticancer treatment, it is important to elucidate the interactions of TKIs with MDR-related transporters as well as to improve the properties that would prevent TKIs from diffusing into lysosomes. These findings not only help to avoid MDR, but also help to define the possible impact of combining TKIs with other anticancer drugs, leading to more efficient therapy and fewer adverse effects in patients.

• Klíčová slova
• ABC transporter, SLC transporter, cancer, lysosomal sequestration, multidrug resistance, tyrosine kinase inhibitor,
• MeSH
• ABC transportéry genetika   metabolismus   MeSH
• biologický transport MeSH
• chemorezistence účinky léků   MeSH
• inhibitory proteinkinas farmakologie   terapeutické užití   MeSH
• klinické zkoušky jako téma MeSH
• lidé MeSH
• lyzozomy účinky léků   metabolismus   MeSH
• membránové transportní proteiny genetika   metabolismus   MeSH
• mnohočetná léková rezistence účinky léků   MeSH
• nádory farmakoterapie   genetika   metabolismus   MeSH
• přehodnocení terapeutických indikací léčivého přípravku * MeSH
• SLC transportéry genetika   metabolismus   MeSH
• výsledek terapie MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• ABC transportéry MeSH
• inhibitory proteinkinas MeSH
• membránové transportní proteiny MeSH
• SLC transportéry MeSH